...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Journal of Surgical Research: Clinical and Laboratory Investigation >Long-term outcomes after hepatic resection combined with radiofrequency ablation for initially unresectable multiple and bilobar liver malignancies
【24h】

Long-term outcomes after hepatic resection combined with radiofrequency ablation for initially unresectable multiple and bilobar liver malignancies

机译：肝切除术后联合射频消融治疗最初无法切除的多发性和双叶肝恶性肿瘤的长期结果

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Background Hepatic resection (HRE) combined with radiofrequency ablation (RFA) offers a surgical option to a group of patients with multiple and bilobar liver malignancies who are traditionally unresectable for inadequate functional hepatic reserve. The aims of the present study were to assess the perioperative outcomes, recurrence, and long-term survival rates for patients treated with HRE plus RFA in the management of primary hepatocellular carcinoma (HCC) and metastatic liver cancer (MLC). Methods Data from all consecutive patients with primary and secondary hepatic malignancies who were treated with HRE combined with RFA between 2007 and 2013 were prospectively collected and retrospectively reviewed. Results A total of 112 patients, with 368 hepatic tumors underwent HRE combined with ultrasound-guided RFA, were included in the present study. There were 40 cases of HCC with 117 tumors and 72 cases of MLC with 251 metastases. Most cases of liver metastases originated from the gastrointestinal tract (44, 61.1%). Other uncommon lesions included breast cancer (5, 6.9%), pancreatic cancer (3, 4.2%), lung cancer (4, 5.6%), cholangiocarcinoma (4, 5.6%), and so on. The ablation success rates were 93.3% for HCC and 96.7% for MLC. The 1-, 2-, 3-, 4-, and 5-y overall recurrence rates were 52.5%, 59.5%, 72.3%, 75%, and 80% for the HCC group and 44.4%, 52.7%, 56.1%, 69.4%, and 77.8% for the MLC group, respectively. The 1-, 2-, 3-, 4-, and 5-y overall survival rates for the HCC patients were 67.5%, 50%, 32.5%, 22.5%, and 12.5% and for the MLC patients were 66.5%, 55.5%, 50%, 30.5%, and 19.4%, respectively. The corresponding recurrence-free survival rates for the HCC patients were 52.5%, 35%, 22.5%, 15%, and 10% and for the MLC patients were 58.3%, 41.6%, 23.6%, 16.9%, and 12.5%, respectively. Conclusions HRE combined with RFA provides an effective treatment approach for patients with primary and secondary liver malignancies who are initially unsuitable for radical resection, with high local tumor control rates and promising survival data.
机译：背景技术肝切除术（HRE）结合射频消融（RFA）为一群传统上因功能性肝储备不足而无法切除的多发性和双叶肝恶性肿瘤患者提供了手术选择。本研究的目的是评估在原发性肝细胞癌（HCC）和转移性肝癌（MLC）的治疗中，接受HRE加RFA治疗的患者的围手术期结局，复发率和长期生存率。方法回顾性分析2007年至2013年间HRE联合RFA治疗的所有原发性和继发性肝癌患者的资料。结果本研究共纳入112例HRE结合超声引导的RFA的368例肝肿瘤。其中HCC 40例，肿瘤117例，MLC 72例，转移251例。多数肝转移病例起源于胃肠道（44，61.1％）。其他不常见的病变包括乳腺癌（5，6.9％），胰腺癌（3，4.2％），肺癌（4，5.6％），胆管癌（4，5.6％）等。 HCC的消融成功率为93.3％，MLC的消融成功率为96.7％。 HCC组的1年，2年，3年，4年和5年的总复发率分别为52.5％，59.5％，72.3％，75％和80％，分别为44.4％，52.7％，56.1％， MLC组分别为69.4％和77.8％。 HCC患者的1、2、3、4和5年总生存率分别为67.5％，50％，32.5％，22.5％和12.5％，而MLC患者为66.5％，55.5 ％，50％，30.5％和19.4％。 HCC患者的相应无复发生存率分别为52.5％，35％，22.5％，15％和10％，而MLC患者分别为58.3％，41.6％，23.6％，16.9％和12.5％。 。结论HRE联合RFA为最初不适合行根治性切除术的原发性和继发性肝恶性肿瘤患者提供了有效的治疗方法，其局部肿瘤控制率高且生存数据令人满意。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号